Qiagen said it is working with Nvidia to integrate accelerated computing and Nvidia’s BioNeMo platform into Qiagen Digital Insights’ curated biomedical knowledgebases. The aim is to increase the use of AI in drug discovery by helping researchers connect biological evidence and query disease mechanisms, targets, pathways, compounds and clinical insights. Qiagen said the combined system will use graph-based AI leveraging retrieval-and-reasoning techniques on biomedical knowledge graphs, along with accelerated computing to support multi-step, agentic drug discovery workflows. The company plans initial pilot programs for select pharma and biotech partners, with broader availability following validation. The partnership reflects ongoing infrastructure investment to turn curated biomedical data into scalable AI workflows for target identification and biomarker discovery.